Visterra is a biologics research and early-stage clinical development company developing therapies for patients with immune-mediated and other hard-to-treat diseases.
Ready to make a meaningful impact?
At Visterra, we champion innovation, teamwork, and perseverance.
You’ll be challenged and empowered to make meaningful impacts as a member of a collaborative, high-performing, agile team.
Our approach is unique.
At Visterra, we believe innovative technologies and approaches are critical to developing novel therapeutics – from cutting-edge computational, AI, and experimental research methods to agile preclinical development, reliable manufacturing, and creative trial designs.
Immunoglobulin A
Nephropathy (IgAN)
Sibeprenlimab (VIS649) is an investigational humanized IgG2 monoclonal antibody being evaluated for the treatment of IgA nephropathy (IgAN), a chronic, progressive kidney disease.
Yarbrough, Jill
“In the words of Hippocrates, ‘Wherever the art of medicine is loved, there is also a love of humanity.’ My colleagues at Visterra embrace this philosophy and the clinical team is very proud and confident of the products we take into the clinic. We are excited to be a part of the journey to bring life… READ MORE>>
“In the words of Hippocrates, ‘Wherever the art of medicine is loved, there is also a love of humanity.’ My colleagues at Visterra embrace this philosophy and the clinical team is very proud and confident of the products we take into the clinic. We are excited to be a part of the journey to bring life changing medicines to patients.”
– Jill Yarbrough, Vice President, Head of Clinical Operations
Committed to extending and improving the lives of people afflicted with immune-mediated diseases.
Our team is fueled by curiosity, guided by the scientific method and innovative clinical research strategies, culminating in novel therapies engineered to augment and surpass standard of care.
